Irun Bhan

Irun Bhan

Auto-generated profile, based on publicly available information

Irun Bhan

Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
NUNneka N. Ufere
Nneka N. Ufere
JDJohn Donlan
John Donlan
LWLauren Waldman
Lauren Waldman
JDJules L. Dienstag
Jules L. Dienstag
LFLawrence S. Friedman
Lawrence S. Friedman
AEAreej El-Jawahri
Areej El-Jawahri

12 September 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MTMartin Samuel Taylor
Martin Samuel Taylor
CWConnie Wu
Connie Wu
PFPeter C. Fridy
Peter C. Fridy
SZStephanie J. Zhang
Stephanie J. Zhang
YSYasmeen Senussi
Yasmeen Senussi
KBKathleen H. Burns
Kathleen H. Burns
Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible expression in normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10−17 mol/L) ORF1p concentrations in plasma across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multianalyte panel, provides early therapeutic response monitoring in gastroesophageal cancers, and is prognostic for overall survival in gastroesophageal and colorectal cancers. Together, these observations nominate ORF1p as a multicancer biomarker with potential utility for disease detection and monitoring. Significance: The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and blood. Ultrasensitive ORF1p assays from as little as 25 μL plasma are novel, rapid, cost-effective tools in cancer detection and monitoring. See related commentary by Doucet and Cristofari, p. 2502. This article is featured in Selected Articles from This Issue, p. 2489

3 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JFJoseph W. Franses
Joseph W. Franses
JPJulia Philipp
Julia Philipp
PMPavlos Missios
Pavlos Missios
IBIrun Bhan
Irun Bhan
ALAnn Liu
Ann Liu
DTDavid T. Ting
David T. Ting
Pancreatic ductal adenocarcinoma (PDAC) lethality is due to metastatic dissemination. Characterization of rare, heterogeneous circulating tumor cells (CTCs) can provide insight into metastasis and guide development of novel therapies. Using the CTC-iChip to purify CTCs from PDAC patients for RNA-seq characterization, we identify three major correlated gene sets, with stemness genes LIN28B/KLF4, WNT5A, and LGALS3 enriched in each correlated gene set; only LIN28B CTC expression was prognostic. CRISPR knockout of LIN28B—an oncofetal RNA-binding protein exerting diverse effects via negative regulation of let-7 miRNAs and other RNA targets—in cell and animal models confers a less aggressive/metastatic phenotype. This correlates with de-repression of let-7 miRNAs and is mimicked by silencing of downstream let-7 target HMGA2 or chemical inhibition of LIN28B/let-7 binding. Molecular characterization of CTCs provides a unique opportunity to correlated gene set metastatic profiles, identify drivers of dissemination, and develop therapies targeting the “seeds” of metastasis.

1 December 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
IBIrun Bhan
Irun Bhan
KMKelly Mosesso
Kelly Mosesso
LGLipika Goyal
Lipika Goyal
JPJulia Philipp
Julia Philipp
MKMark Kalinich
Mark Kalinich
DTDavid T. Ting
David T. Ting

1 July 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
MAMaen Abdelrahim
Maen Abdelrahim
AMAlejandro Mejia
Alejandro Mejia
Abdullah EsmailAbdullah Esmail
Abdullah Esmail
JGJuan Carlos Barrera Gutierrez
Juan Carlos Barrera Gutierrez
MOMahmoud Ouf
Mahmoud Ouf
AHAiwu Ruth He
Aiwu Ruth He
PURPOSE: Hepatocellular carcinoma (HCC) has high relapse rates after standard-of-care (SOC) resection or liver transplantation (LT). We evaluated the utility of circulating tumor DNA (ctDNA) to predict relapse/progression risk in patients with HCC. Materials and Methods: This retrospective analysis examined real-world data from ctDNA testing on 125 patients with HCC (721 plasma samples) undergoing curative-intent treatments and SOC management. Patients were divided into four subcohorts: cohort A (n = 64) and B (n = 52) comprised patients under recurrence monitoring after LT or resection, respectively. Cohort C (n = 4) and D (n = 5) comprised patients under treatment response monitoring with known recurrence or inoperable disease, respectively. A personalized, tumor-informed 16-plex polymerase chain reaction next-generation sequencing assay (Signatera, Natera, Inc, Austin, TX) was used for ctDNA testing. The molecular residual disease (MRD) window was defined as 2-12 weeks post-LT/resection (cohorts A/B), before starting adjuvant therapy (AT). Surveillance window was defined as post-MRD window or 2 weeks post-AT (cohort B) or during ongoing treatment (cohorts C/D). RESULTS: The median follow-up was 40 (1.5-60) months. In cohort A, 97.2% (35/36) of patients with ctDNA negativity in the MRD window remained negative during surveillance. In cohort B, ctDNA was detected in 29.4% (10/34) of patients within the MRD window, all of whom experienced clinical recurrence (hazard ratio [HR], 7.2 [95% CI, 2.6 to 20]; P < .0001). In the surveillance window (cohort B), the ctDNA detection rate was 32.3% (10/31), and all experienced recurrence (HR, 18.0 [95% CI, 3.9 to 85]; P < .0001). In cohorts C/D, on-treatment ctDNA dynamics were concordant with treatment response as measured by imaging. Compared with alpha-fetoprotein, ctDNA had higher sensitivity and a significantly longer lead time (7.9 v 2.2 months) for recurrence detection. CONCLUSION: Serial ctDNA testing effectively identified HCC recurrence early, postresection and post-LT. ctDNA was also useful for treatment response monitoring and could help resolve ambiguous imaging results.

17 June 2021 in JCO Precision Oncology
Verified
Journal Article
Open access
JFJoseph Franses
Joseph Franses
IBIrun Bhan
Irun Bhan
APAmaya Pankaj
Amaya Pankaj
DTDavid T. Ting
David T. Ting
VDVikram Deshpande
Vikram Deshpande
KTKenneth Tanabe
Kenneth Tanabe